Matthew Ronsheim - 20 May 2024 Form 4 Insider Report for Innoviva, Inc. (INVA)

Reporting relationship: Officer
Issuer ticker: INVA
Reported as of: 20 May 2024
Net transaction value: -$4,323
SEC form: 4
Accepted by SEC: 21 May 2024, 20:15:25 UTC
Prior SEC filing: 07 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Matthew Ronsheim

Key filing fact

Matthew Ronsheim filed Form 4 for Innoviva, Inc. (INVA) on 21 May 2024.

Key facts

This page summarizes Matthew Ronsheim's Form 4 filing for Innoviva, Inc. (INVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 May 2024, 20:15.

Change

Previous filing in this sequence was filed on 07 Mar 2024.
Current net transaction value: -$4,323.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INVA transaction

Common Stock

Tax liability

Transaction value: $4,323
Shares: -268
Change %: -0.66%
Price: $16.13
Shares after: 40,510
Date: 20 May 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.

SEC remarks

Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.